RVO

PERFORMANCE YOU CAN TRUST
,

Give your eligible

RVO
patients extended injections visits through fast and sustained drying, with 4x the molar dose of a tried-and-tested molecule.,

  • Mean CRT reductions in the EYLEA 8mg 8q8/3 arm (QUASAR) were -342.5 µm 4 weeks after 1 dose and reduction was maintained through to Week 64.,

 

EYLEA 8mg is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DME) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).

EYLEA 8mg offers a flexible posology in RVO with only 3 loading doses.

MoA

Suppress VEGF for longer vs EYLEA 2mg
†
,

A 34% slower ocular clearance rate, can result in 6 weeks longer VEGF suppression than EYLEA 2mg†,

QUASAR DATA*

Fast and sustained drying in RVO
‡
,

Mean CRT reductions with EYLEA 8mg in 8q8/3 was -342.5 µm 4 weeks after 1 dose and -361 µm from baseline to Week 64,

QUASAR DATA*

Fewer injections with
EYLEA 
8mg in RVO

Vision gains were sustained through Week 64 with ~3 fewer injections (p<0.0001)§¶, with~ 9 in 10 patients achieving last assigned interval of ≥3 months in the 8Q8/3 treatment armII,

*QUASAR was a multicentre, double-masked study in patients with treatment-naïve macular edema secondary to RVO. Patients were randomised to receive EYLEA 2Q4 (n=301), EYLEA 8Q8/3 (n=293) or EYLEA 8Q8/5 (n=298). Further information about the QUASAR study can be found further down the page.

†The impact of molecular properties on clinical outcomes is yet to be defined. Suppression is based on a PK/PD model. This is a hypothetical illustrative model based on in vitro data and should be interpreted with caution.

‡CRT reduction was observed 4 weeks after the first loading dose with EYLEA 8mg.

§Key secondary endpoint.

¶Vision gains were achieved across BRVO and CRVO/HRVO types.

‖In QUASAR, patients in the 8Q8/3 and 8Q8/5 groups had 3 and 5 initial monthly injections, respectively, before being extended to Q8 intervals, with the opportunity for extension or shortening based on DRM criteria.

In the video above (5 minutes), Prof. Varun Chaudhary presents the QUASAR 64-week data.

QUASAR

Deliver vision gains, sustained with fewer injections
,

Mean of ~3 fewer injections required over 64 weeks with EYLEA 8mg vs EYLEA 2mg (27% reduction, 8.5 vs 11.7, p<0.0001)*

 

QUASAR primary endpoint (non-inferior vision gains at week 36) met:

  • 17.4 letters average gain from baseline at Week 36 with EYLEA 8mg vs 17.5 with EYLEA 2mg (p<0.0001)†‡§,
LS mean change in BCVA from baseline through Week 64 (FAS)

EYLEA 8mg improved vision from baseline regardless of RVO subtype (BRVO or CRVO/HRVO).

BRVO_LS mean change in BCVA from baseline through Week 36 (FAS)
CRVO_HRVO_LS mean change in BCVA from baseline through Week 36 (FAS)

*With a two-sided inferiority test.
†Vision gains were for the 8Q8/3 arm and this posology is consistent with the SmPC.
‡One-sided non-inferiority.
§EYLEA 8mg improved vision from baseline regardless of RVO subtype (BRVO or CRVO/HRVO).
¶Missing endpoint values imputed using a multiple imputation procedure. Estimates based on a linear regression model, within the multiple imputation procedure, adjusted for BL BCVA, BL CRT and stratification variables (geographic region [Japan vs Asia-Pacific vs Europe vs America], BCVA score [>60 vs ≥60], RVO type [CRVO/HRVO vs BRVO]).

Abbreviations

2Q4, aflibercept 2mg administered every 4 weeks; 2Q8, aflibercept 2mg administered every 8 weeks; 8Q8/3, aflibercept 8mg administered every 8 weeks, after 3 monthly injections at 4-week intervals; 8Q8/5, aflibercept 8mg administered every 8 weeks, after 5 monthly injections at 4-week intervals; 8Q12, aflibercept 8mg administered every 12 weeks; 8Q16, aflibercept 8mg administered every 16 weeks; AE, adverse event; APTC, AntiPlatelet Trialists’ Collaboration; BCVA, best-corrected visual acuity; BL, baseline; BRVO, branch retinal vein occlusion; CRT, central retinal thickness; CRVO, central retinal vein occlusion; DMO, diabetic macular oedema; DRM, dose regimen modification; ETDRS, Early Treatment Diabetic Retinopathy Study; FAS, full analysis set; HRVO, hemi-retinal vein occlusion; IOI, intraocular inflammation; LS, least squares; MoA, mechanism of action; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion; SAE, serious adverse event; SAF, safety analysis set; SD, standard deviation; SD-OCT, spectral-domain optical coherence tomography; T&E, treat and extend; TEAE, treatment-emergent adverse event; Wk, week.

PP-EYL_8mg-IL-0117-1

    • 1
      EYLEA® 8mg SmPC as approved by the Israeli MoH.
    • 2
      Gale R, et al. Aflibercept 8mg in retinal vein occlusion: Primary endpoint results from the QUASAR study. Angiogenesis, Exudation, and Degeneration. 8 February 2025. Virtual. Oral presentation.
    • 3
      Schubert W, et al. Transl Vis Sci Technol 2022;11:36.
    • 4
      EMA. EYLEA EPAR assessment report 2023. Available at: https://www.ema.europa.eu/en/documents/variation-report/eylea-h-c-2392-x-84-g-epar-assessment-report-variation_en.pdf. Accessed: February 2026.
    • 5
      Wykoff C, et al. Aflibercept 8mg for retinal vein occlusion: Outcomes of the QUASAR Phase 3 randomized trial by RVO type, CRVO/HRVO, or BRVO. AAO. 18–20 October 2025. Orlando, USA. Oral presentation.
    • 6
      Bayer Data on File. REF-EYL-ALL-2483. October 2025.
    • 7
      Chaudhary V, et al. Aflibercept 8mg in macular edema following retinal vein occlusion: Week 64 results from the QUASAR trial. Angiogenesis, Exudation, and Degeneration. 7 February 2026. Virtual. Oral presentation.